The guideline has been condensed into two papers, the first detailing definitions, classification, diagnosis, imaging, pathology, and management of special situations [EIMs, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders of UC]; and the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].
The strategy to define consensus was similar to that previously described in other ECCO consensus guidelines [available at www. ecco-ibd.eu]. Briefly, an open call for participants was made, with participants selected by the Guidelines' Committee of ECCO [known as GuiCom] on the basis of their publication record and a personal statement. Working parties were established to review the consensus statements published in 2012, 1-3 after which a recommendation was issued on whether they required revision based upon advances in the published literature. There was agreement that extensive review of histopathology, endoscopy, OI, anaemia, EIMs, surgery, and pregnancy was not required, as these subjects are reviewed in other recent ECCO guidelines 7, [11] [12] [13] [14] [15] [16] ; rather, abbreviated text and selected statements from these guidelines specific to UC are provided. Paediatric UC is dealt with in a separate ECCO initiative 17 which is currently being updated. Provisional ECCO statements and supporting text were written following a comprehensive literature review, then refined following two voting rounds which included national representative participation by ECCO's 35 member countries. The level of evidence was graded according to the Oxford Centre for Evidence-Based Medicine [www.cebm.net]. The ECCO statements were finalised by the authors at a meeting in Barcelona in October 2015 and represent consensus with agreement of at least 80% of participants. Consensus statements are intended to be read in context with their qualifying comments and not in isolation. The supporting text was then finalised under the direction of each working group leader [FM, FC, AD, PG, FR] , including an updated literature search to October 2016 of the most relevant [eight] journals, before being integrated by a consensus leader [MH] . This consensus guideline is pictorially represented within the freely available ECCO e-Guide [http://www.e-guide.ecco-ibd.eu/].
Section 1. Definitions

Introduction
UC is a lifelong disease arising from an interaction between genetic and environmental factors, observed predominantly in developed countries. Its precise aetiology is unknown, and therefore curative medical therapy is not yet available. Within Europe there is an east-west and north-south gradient, but the incidence appears to have increased in southern and eastern countries during recent years. [18] [19] [20] Patients may live with a considerable symptom burden and high risk of disability 21 despite medical treatment. 22 Clinicians must advise and treat patients on the basis of currently available information. Despite robust evidence from rigorously conducted randomised trials, the strict and somewhat necessarily restrictive inclusion and exclusion criteria in trial design may limit translation of such evidence to 'real-world' patients.
Definitions
Ulcerative colitis [UC] is a chronic inflammatory condition that causes continuous mucosal inflammation of the colon, usually without granulomas on biopsy. It affects the rectum and to a variable extent the colon in a continuous fashion, and is characterised by a relapsing and remitting course. 23 Inflammatory bowel disease unclassified [IBDU] is the term best suited for a minority of cases in which a definitive distinction between UC, Crohn's disease, or other causes of colitis cannot be made after taking into account the history, endoscopic appearance, histopathology of multiple mucosal biopsies, and appropriate radiology. 23, 24 Indeterminate colitis is a term reserved for pathologists to describe a colectomy specimen with overlapping features of UC and Crohn's disease. 24, 25 Detailed information on definitions can be found in Supplementary material, available as Supplementary data at ECCO-JCC online. 1, 23, 24, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Section 2. Classification
Classification according to disease extent
ECCO statement 2A
Disease extent influences treatment modality, whether oral and/or topical therapy [EL1] , and determines onset and frequency of surveillance [EL2] . It is defined by the maximal macroscopic extent at colonoscopy, classified as proctitis, left-sided colitis, and extensive colitis Extent of inflammation influences the patient's management and the choice of delivery system for a given therapy. For example, topical therapy in the form of suppositories or enemas is usually the firstline choice for proctitis and left-sided colitis, respectively, whereas oral therapy [often combined with topical therapy] is appropriate for extensive colitis. Extent of colitis influences the risk of development of dysplasia or colorectal cancer [CRC] , and thus the start and the frequency of colonoscopic surveillance. [40] [41] [42] Patients with extensive colitis have the highest risk of developing CRC, whereas those with proctitis alone have a risk similar to the general population. Patients with left-sided colitis [including procto-sigmoiditis] carry an intermediate risk; however, their risk approaches that of patients with extensive colitis as disease duration increases. [43] [44] [45] [46] Therefore, patients with left-sided and extensive colitis are generally advised to have surveillance colonoscopy, whereas patients with proctitis do not need such surveillance 46 [see Section 8]. It should be noted that the macroscopic extent at colonoscopy may underestimate the extent of disease as compared with histology, and biopsies are necessary to determine the full extent of colonic inflammation, providing prognostic information and risk stratification for dysplasia surveillance.
13,47-51 Proximal extension of proctitis or left-sided colitis may occur in 20-50% of adult patients with UC. [52] [53] [54] 2.2. Classification according to disease severity 2.2.1. Activity and pattern of disease It should be standard practice to confirm the presence of active colitis by flexible sigmoidoscopy and biopsy before starting treatment, which may identify unexpected causes of symptoms that mimic active disease such as cytomegalovirus [CMV] colitis, rectal mucosal prolapse, Crohn's disease, malignancy, or even irritable bowel syndrome and haemorrhoidal bleeding. In addition, all patients with presumed active disease require stool cultures including Clostridium difficile toxin assay to exclude enteric infection. Patients with an appropriate travel history should also have stool microscopy to exclude parasitic infections.
In a population-based study from Copenhagen County, approximately 50% of patients are in clinical remission at any time during a given year. 55 However, 90% had a cumulative probability of a relapsing course after 25 years of follow-up. Disease activity in the first 2 years after diagnosis indicated [probability 70% to 80%] an increased likelihood of five consecutive years of active disease. In a Norwegian study involving 781 patients, an inverse relationship was noted between the time to first relapse and the total number of relapses over a 10-year period. 56 In the IBSEN cohort, the 10-year cumulative relapse rate was 83%, whereas patients older than 50 years had a significantly reduced relapse rate. 28 In clinical trials designed for the maintenance of remission in patients with clinical remission at baseline, clinical relapse rates among patients receiving placebo range from 29% to 43% at 6 months, and from 38% to 76% at 12 months. 33, 57, 58 A population-based study carried out in the county of Copenhagen 59 described the outcome in 1575 patients in the first 5 years following diagnosis of UC between 1962 and 2005. In the most recent period, the percentage of patients experiencing an 'indolent' course [no relapse during the first 5 years after diagnosis] was 13%, 74% had a 'moderate' course [two or more relapses within the first 5 years, but less than every year], and 13% had an 'aggressive' course [disease activity at least every year during the first 5 years].
Microscopic involvement is also important. In quiescent UC, a chronic inflammatory cell infiltrate was present in all biopsy specimens and crypt architectural irregularities were seen in two-thirds; 52% of patients with an acute inflammatory cell infiltrate relapsed after 12 months of follow-up, compared with 25% who relapsed without such an infiltrate [p = 0.02] . Similarly, relapse rates were higher in those with crypt abscesses, mucin depletion, and mucosal breaks. 60 The degree of microscopic bowel inflammation is also a risk factor for CRC in patients with long-standing, extensive UC. 
Clinical and laboratory markers of severity
Among objective clinical features, bloody stool and frequency, body temperature, and heart rate are good predictors of outcome. Laboratory markers have been studied extensively with varying degrees of success. The widely used acute phase C-reactive protein [CRP] is not as useful in UC as it is in Crohn's disease for the assessment of disease activity, except in acute severe colitis where standard values have been established both for adults and children. [61] [62] [63] In patients receiving parenteral steroids, a raised CRP > 45 mg/l 48 to 72 h following hospital admission for severe colitis together with three to eight stools a day is highly predictive for colectomy. 64 Elevated erythrocyte sedimentation rate [ESR] , elevated serum procalcitonin, 65 and [low] albumin levels have been studied, but none has been demonstrated to be superior to CRP. 66 The most studied stool markers are faecal calprotectin and lactoferrin, though other markers such as elastase and S100A12 have also shown accuracy at detecting colonic inflammation. [67] [68] [69] [70] [71] Calprotectin has value for diagnosis and assessment of disease severity [having a good correlation with endoscopic indices, relapse, and response to treatment]. [72] [73] [74] [75] [76] Calprotectin can be used as a marker for relapse in patients with inactive inflammatory bowel disease [IBD] . Doubling of calprotectin levels was associated with an increased risk of relapse (hazard ratio [HR]: 2.01; 95% confidence interval [CI]: 1.52-2.65). It must be stressed, however, that none of these markers is specific for UC, since they mostly represent active colonic inflammation.
Remission
As with disease activity, there is no fully validated definition of remission. The consensus group agreed that the best way to define remission is a combination of clinical parameters [stool frequency ≤ 3/day with no bleeding] and no mucosal lesions at endoscopy. UC primarily presents in late adolescence and early adulthood, although the diagnosis may be made at any age. A small peak in incidence has been demonstrated in some populations after the fifth decade of life.
102 UC appears to affect both sexes equally. The inflammation characteristically commences in the rectum and extends proximally in a continuous, confluent, and concentric manner to affect a variable extent of the colon, or its entire mucosal surface. The proximal extent of inflammation may progress or regress over time, but after disease regression the distribution of inflammation tends to match the extent of previous episodes in the event of relapse. The view that UC represents continuous colonic inflammation has, however, been challenged by reports of a rectal sparing variant [more common in PSC] and peri-appendiceal patchy inflammation.
103
More than 90% of patients with active UC report having rectal bleeding. Associated symptoms generally reflect the severity of mucosal disease, and may differ according to disease extent. [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] Loose stools [a decrease in stool consistency] for more than 6 weeks differentiates extensive UC from most cases of infectious diarrhoea. 115 Patients with active disease also complain of rectal urgency, tenesmus, mucopurulent exudate, nocturnal defaecation, and crampy abdominal pain. In contrast, patients with proctitis usually present with rectal bleeding, urgency, tenesmus, and occasionally severe constipation. 107, 109 Although simple fistulae may occasionally occur in UC, recurrent or complex perianal fistulae should always raise the suspicion of Crohn's colitis.
116
The onset of UC is usually insidious; symptoms are often present for weeks or even months before medical advice is sought. Presentation with a severe attack occurs in about 15%, with systemic symptoms including weight loss, fever, tachycardia, nausea, and vomiting. 27, 117, 118 EIMs, in particular axial or peripheral arthropathy, episcleritis, and erythema nodosum may accompany the presentation in about 10-20% of cases and can precede intestinal symptoms in 10% of patients. 7, [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] 
Risk factors for ulcerative colitis
Relatives of patients with UC have an increased risk of developing the disease. 133 The risk of UC is greatest in first-degree relatives (incidence rate ratio [IRR]: 4.08; 95% CI: 3.81-4.38), but is also raised in second-degree [IRR: 1.85; 95% CI: 1.60-2.13], and thirddegree relatives [IRR: 1.51; 95% CI: 1.07-2.12] of UC patients, as well as in relatives of patients with Crohn's disease although in a less pronounced fashion.
134
Tobacco intake protects against and reduces the severity of UC, 56,135-137 but may not improve the natural history of the disease. 138 In contrast, ex-smokers have approximately a 70% higher risk of developing the disease, which is often more extensive and refractory to treatment compared with individuals who have never smoked. [139] [140] [141] Smoking might protect against PSC or pouchitis, but the data are inconsistent. [142] [143] [144] Appendicitis and mesenteric lymphadenitis during childhood or adolescence are linked to a reduced risk of UC in adulthood. 102, [145] [146] [147] [148] [149] [150] The protective effect of appendectomy is additional to that of smoking, but does not appear to protect against the development of PSC. 151 When appendectomy is performed after the onset of UC, the effect [if any] on the course of disease is less clear and is subject to ongoing research.
152
Non-selective non-steroidal anti-inflammatory drugs [NSAIDs] may exacerbate the disease. 56, [139] [140] [141] [153] [154] [155] [156] [157] In contrast, preliminary evidence from open-label studies and a double-blind controlled trial suggests that short-term treatment with selective COX-2 inhibitors is safe. 
ECCO statement 2D
The routine clinical use of genetic or serological molecular markers is not recommended for the classification of ulcerative colitis [EL2]
ECCO statement 3A
Symptoms of ulcerative colitis are dependent upon extent and severity of disease and include bloody diarrhoea, rectal bleeding, tenesmus, urgency, and faecal incontinence. Nocturnal defaecation and fatigue are often reported. Increasing bowel frequency, abdominal pain, anorexia, and fever suggest severe colitis [EL5] The diagnosis of UC is suspected in the context of compatible clinical symptoms. Infectious or drug-induced forms of colitis should be excluded. Family history and EIMs should be discussed. 7, [159] [160] [161] [162] [163] [164] 
Examination
Findings on physical examination depend on the extent and severity of disease. Examination of patients with mild or moderate activity is usually unremarkable, apart from blood on rectal examination. Patients with a severe attack may exhibit fever, tachycardia, weight loss, abdominal tenderness, abdominal distension, and reduced bowel sounds. 
Diagnosis
The natural history of UC is characterised by episodes of relapse and periods of remission. An unremitting, continuous course occurs in approximately 5% of the cases, as does a single acute episode followed by prolonged remission. 55 The IBSEN study noted that approximately 60% of patients experienced a decrease in symptoms over time. 56 The frequency of relapse [pattern of disease] is usually defined during the first 3 years, and may be characterised as continuous [persistent UC symptoms without remission], frequent [≧ 2 relapses/year] or infrequent [≦ 1 relapse/year]. 39 In the recent Epicom study, the proportion of patients with UC in remission rose from 11% at the time of diagnosis to 71% after 1 year of follow-up. 27 It is important to rapidly establish the diagnosis, extent, and severity of disease, as these influence treatment options and possibly disease progression. 114 It is unreasonable to expect the histopathological analysis alone to lead to a diagnosis, but normal mucosal biopsies effectively exclude active UC as the cause of symptoms. In 10% of patients, the diagnosis may change to Crohn's disease or be refuted during the first 5 years. 
Microbial investigations
Nosocomial C. difficile infection is a growing health problem and has been associated with higher mortality and health resources' utilisation.
172-177 ECCO guidelines now recommend screening with every disease flare.
11 Moreover, microbial stool tests should be performed in the case of treatment-refractory or severe relapse. [178] [179] [180] [181] [182] Reactivation of CMV can occur in UC, particularly [but not invariably] in immunosuppressed patients with severe colitis. [183] [184] [185] Although CMV reactivation may not cause disease relapse, CMV infection can cause refractory or severe relapses. It should be excluded in patients who relapse while receiving immunosuppressant therapy. The optimal method for detecting clinically relevant CMV infection in patients with colitis has not been established, but most experts agree it requires histology/immunohistochemistry rather than polymerase chain reaction [PCR] detection of CMV in the blood. Occasional intranuclear inclusion bodies consistent with CMV on histopathology do not necessarily indicate clinically significant infection, but multiple intranuclear inclusions are usually significant. 169, [186] [187] [188] Further detail, including information on therapy, can be reviewed in the ECCO Consensus on OIs 11 and in a recent review. 
Biomarkers
The most widely studied serological markers are perinuclear antineutrophil cytoplasmic antibodies [pANCAs] and anti-Saccharomyces cerevisiae antibodies [ASCAs] . Usually, pANCAs are detected in up to 65% of patients with UC and in less than 10% of patients with Crohn's disease. 190, 191 Given the current limited sensitivity of these markers, their routine use for the diagnosis of UC and for therapeutic decisions is not clinically justified.
ECCO statement 3D
Physical examination should include pulse, blood pressure, temperature, weight and height, and abdominal examination for distension and tenderness. Several neutrophil-derived proteins such as calprotectin, elastase, lysozyme, and lactoferrin have been evaluated as markers of intestinal inflammation in IBD. [192] [193] [194] [195] Of these, faecal calprotectin appears to be the most sensitive. 196 Multiple studies emphasise the value of calprotectin in selecting patients for diagnostic investigation, in the assessment of disease severity [it correlates well with endoscopic indices], and in the diagnosis of relapse and response to treatment. [72] [73] [74] [75] 197 As with all faecal tests, calprotectin lacks the specificity to discriminate between different types of inflammation; nevertheless, it represents a useful non-invasive marker in the follow-up of UC patients. 198, 199 Home-based calprotectin assessment provides a rapid method to measure gut inflammation and seems to be a reliable alternative to enzyme-linked immunosorbent assay [ELISA] ; it presents a new way of monitoring patients by eHealth. 
. Rectal sparing and caecal patch
Macroscopic and microscopic rectal sparing has been described in untreated children with UC. [201] [202] [203] In adults, a normal or patchy inflammation in the rectum is more likely to occur due to topical therapy. 204, 205 Patchy inflammation in the caecum is referred to as a 'caecal patch' and may be observed in patients with left-sided colitis. In the presence of macroscopic and histological rectal sparing or a caecal patch in newly diagnosed colitis, evaluation of the small bowel in addition to an ileo-colonoscopy is recommended. The natural history of patients with patchy right colonic inflammation seems to be similar to those with isolated left-sided UC. 187, 190 
Appendiceal skip lesions
Involvement of the appendix as a skip lesion is reported in up to 75% of patients with UC. 206 Appendiceal inflammation has been associated with a more responsive course and a higher risk of pouchitis after ileal pouch anastomosis. [207] [208] [209] [210] Although both findings require confirmation, a recent retrospective study reported a similar clinical course in patients with an atypical distribution of inflammation when compared with those with a typical distribution in terms of remission, relapse, disease extension, colectomy, and mortality. 
Backwash ileitis
Continuous extension of macroscopic or histological inflammation from the caecum into terminal ileum is termed 'backwash ileitis', and is observed in up to 20% of patients with extensive colitis. Rarely, ileal erosions may occur in patients without caecal involvement, which challenges the pathogenic theory that maintains that backwash ileitis stems from a reflux of caecal contents into the ileum. [212] [213] [214] Patients with backwash ileitis seem to be prone to a more refractory course of disease 213 which may include an increased risk of colon neoplasia in proctocolectomy specimens. 215 However, it does not appear to be correlated with poor pouch outcomes.
216
Additional imaging of the small bowel should be considered in cases of macroscopic backwash ileitis, to differentiate UC from Crohn's disease. 
Small bowel
Activity indices
The original classification of severe UC was proposed by Truelove and Witts in 1955. 32 This classification is still considered to be the gold standard for rapid identification of outpatients in need of immediate admission to hospital and intensive treatment. A plain abdominal radiograph should be performed to exclude colonic dilatation [≧ 5.5 cm] and to estimate the extent of disease and look for features that predict response to treatment. The proximal extent of disease broadly correlates with the distal distribution of faecal residue; in a study reporting 51 episodes of severe colitis, the extent of disease was overestimated in 18% and underestimated in 8%. 64 The presence of mucosal islands [small, circular opacities representing residual mucosa isolated by surrounding ulceration] or more than two gas-filled loops of small bowel is associated with a poor response to treatment. 220, 221 Flexible sigmoidoscopy should confirm the diagnosis of severe colitis and help exclude infection, particularly CMV. 183, 184, 222 Empirical treatment may be required if CMV is strongly suspected [such as a patient on IMs with high fever], in which case urgent histopathology should be requested, potentially with a diagnosis within 4 h. Phosphate enema preparation before flexible sigmoidoscopy is considered safe. 223 Full colonoscopy in patients with acute severe colitis is not recommended, in particular in patients on corticosteroids. 224 Endoscopic criteria for severe colitis include haemorrhagic mucosa with deep ulceration, mucosal detachment on the edge of these ulcerations, and well-like ulceration, 225,226 all of which can be assessed by flexible sigmoidoscopy.
Reassessment of extent and severity
ECCO statement 3H
Instruments for measuring clinical and/or endoscopic disease activity in ulcerative colitis are available. The incorporation of a simple clinical and/or endoscopic scoring system is desirable, to improve care of ulcerative colitis patients and to enhance a standardised IT system for inflammatory bowel disease [EL5] . Immediate admission to hospital is warranted for all patients fulfilling criteria for severe colitis, to prevent delayed decision making which may lead to increased perioperative morbidity and mortality [EL4]
ECCO statement 3I
Endoscopic remission is predictive of good outcome [EL2] . Endoscopic reassessment is appropriate at relapse, for steroid-dependent or -refractory ulcerative colitis or when considering colectomy [EL5] Despite the importance of disease location in determining prognosis, risk of cancer, and choice of therapy, the appropriateness of periodic restaging after index colonoscopy has never been studied. In a Norwegian population-based cohort study, mucosal healing after 1 year of treatment was associated with a low risk of future colectomy, necessary in 1.6% of the patients with mucosal healing compared with 7% of those without healing.
227 Another study showed 40% of patients who achieved endoscopic remission-defined as a lack of significant inflammation at endoscopy and on rectal biopsy-remained asymptomatic during 1 year of follow-up, in contrast to only 18% of patients that failed to achieve endoscopic remission.
228 A hospital-based inception cohort analysis in patients with newly diagnosed UC, who were prescribed corticosteroid therapy, evaluated the disease course using clinical [Powel-Tuck] and endoscopic [Baron] indices after 3 and 6 months and then every 6 months. Outcomes at the third month [early response] were used to identify patients with complete, partial, or no response. After 5 years, significant differences between complete and partial responders in the rates of hospitalisation, immunosuppressive therapy, and colectomy were noted. Absence of mucosal healing was the only factor associated with negative outcomes and a more aggressive disease course.
229 A prospective multicentre study analysed patients with active, mild-to-moderate UC treated with oral and rectal mesalamine. Those in clinical remission that presented with less severe endoscopic scores-defined as normallooking mucosa with only mild redness and/or friability-were less likely to relapse after 1 year than patients solely in clinical remission. 3.5. Endoscopy, ultrasound, and colonography
Endoscopic features
Endoscopic changes characteristically commence at the anal verge and extend proximally in a continuous, confluent, and concentric fashion. The demarcation between inflamed and normal areas is usually clear and may occur abruptly within millimetres, especially in distal disease.
A wide variation in the endoscopic interpretation of disease activity is acknowledged.
231 Granularity, vascular pattern, ulceration, and bleeding and/or friability have been reported to predict the global assessment of endoscopic severity 232 ; bleeding and friability are determinants within the Mayo score for UC, which is widely used for clinical trial recruitment [see 231 This is the first validated endoscopic index of severity in UC. The final UCEIS score is the sum of all three descriptors in the worst affected area of the colon visible at sigmoidoscopy. Although the original version of the UCEIS 231 attributed a score of 1 to the normal appearance of a descriptor, a decision was made to change the numbering of the levels: a normal appearance now corresponds to a score of 0, so that the simple sum of the UCEIS ranges from 0 to 8.
233
The endoscopic features of mild inflammation are erythema, vascular congestion, and at least partial loss of the visible vascular pattern. Moderately active colitis is characterised by a complete loss of vascular pattern, blood adherent to the surface of the mucosa, and erosions, often with a coarse granular appearance and mucosal friability [bleeding to light touch]. Severe colitis is characterised by spontaneous bleeding and ulceration 103, 231, [233] [234] [235] [see 
Colonic stenosis in ulcerative colitis
In long-standing UC, a colonic stricture signals an increased risk for CRC and requires careful histological assessment. 245 Initially the
ECCO statement 3J
The most common endoscopic feature of ulcerative colitis is continuous, confluent colonic involvement with clear demarcation of inflammation and rectal involve- : mucosal architecture, lamina propria cellularity, neutrophil granulocyte infiltration, and epithelial abnormality.
Additional detailed information on microscopic features, specifically on the four main categories, can be found in Supplementary material, available as Supplementary data at ECCO-JCC onl ine.
14,169,247-254
Microscopic features-appraisal of the diagnosis
Early stage disease
Not all the microscopic features found in UC are observed in early stage disease; only about 20% of patients show crypt distortion within 2 weeks of the first symptoms of colitis. The distinction from infectious colitis [acute self-limiting colitis], which is characterised by preserved crypt architecture and acute inflammation, is therefore a major concern. 14,169
Focal or diffuse basal plasmacytosis has been recognised as the earliest feature with the highest predictive value for UC diagnosis. It can be identified in 38% of patients within 2 weeks after symptoms presentation. During this period, the distribution pattern of basal plasmacytosis is focal, but may eventually change into a diffuse pattern throughout the disease course. 250 Widespread mucosal or crypt architectural distortion, mucosal atrophy, and an irregular or villous mucosal surface appear later during the evolution of disease [at least 4 weeks after presentation].
Established disease
The exact number of features needed for UC diagnosis has not been established. A correct diagnosis of UC is reached in approximately 75% of cases where two or three out of the four following features occur: severe crypt architectural distortion; severe decreased crypt density; an irregular surface; and heavy diffuse transmucosal inflammation, in the absence of genuine granulomas. 251, 255 In an untreated patient, UC presents a typical pattern of continuous inflammation that begins in the rectum and extends proximally with a gradual decrease in severity. The transition between the involved and the normal mucosa is abrupt.
14,169 However, unusual distribution patterns can occur.
In long-standing disease, the extent of gut involvement decreases during the natural evolution of the disease or after efficient therapy. Histology may show atypical features, such as change from continuous to discontinuous inflammation ['patchiness'] and/or restoration of the rectal mucosa [rectal sparing]. 204, 248, 256 Awareness of these morphological features is important to avoid misdiagnosis, in particular the erroneous change of diagnosis to Crohn's disease. 14, 168 Quiescent [or clinically inactive] disease is characterised by the lack of active inflammation, i.e. mucosal neutrophils, whereas features related to chronic mucosal injury, such as crypt distortion and atrophy as well as Paneth cell metaplasia, may persist. 14, 169, 257 Histological mucosal healing is characterised by the resolution of
ECCO statement 4C
Basal plasmacytosis is the earliest diagnostic feature with the highest predictive value for the diagnosis of ulcerative colitis [EL 3] . Preserved crypt architecture and the absence of a transmucosal inflammatory cell infiltrate do not rule out ulcerative colitis at an early stage. Repeat biopsies after an interval may help to solve differential diagnostic problems and establish a definitive diagnosis by showing additional features [EL 5]
ECCO statement 4D
The microscopic diagnosis of ulcerative colitis is based upon the combination of widespread crypt architectural distortion and mucosal atrophy, and a diffuse transmucosal inflammatory infiltrate with basal plasmacytosis, with active inflammation causing cryptitis and crypt abscesses [EL 2]
ECCO statement 4E
A decreasing gradient of inflammation from distal to proximal favours a diagnosis of ulcerative colitis [EL5] . Treatment may change the classical distribution pattern of inflammation. Awareness of these treatment-related effects is important in the evaluation of biopsies from treated patients to avoid misdiagnosis [EL3]
ECCO statement 4F
In quiescent disease, the mucosa may still show features related to architectural damage and recovery, as well as disappearance of basal plasmacytosis and increased transmucosal cellularity. Active inflammation is usually not observed [EL 3]
ECCO statement 4A
For a reliable diagnosis of ulcerative colitis, a minimum of two biopsies from at least five sites around the colon [including the rectum] and the ileum should be obtained [EL 2]
ECCO statement 4B
Biopsies should be accompanied by clinical information, including endoscopic findings, duration of disease and current treatment. Samples should be fixed immediately by immersion in buffered formalin or an equivalent solution before transport [EL 5] crypt architectural distortion and inflammatory infiltrate.
14 However, the mucosa can still show some features of sustained damage, such as decreased crypt density with branching and atrophy [shortening] of crypts. Reduced epithelial regeneration will usually reduce mucin depletion, i.e. restore the mucin content of epithelial cells.
14,168
Microscopic features-disease activity
Disappearance of mucosal inflammation following treatment has been observed 205 ; thus biopsies can be used to distinguish between quiescent and active disease, as well as to assess the different grades of disease activity.
14 Different scoring systems have been introduced for this purpose, particularly in therapeutic trials. 60, [257] [258] [259] [260] [261] No standard definition of histological remission or 'histological mucosal healing' exists. 257 As a consequence, definitions of pathological remission range from residual inflammation with persistent architectural distortion, to normalisation of the colonic mucosa.
257
Several histological features-such as epithelial damage in association with neutrophils, persistence of an increased transmucosal lamina propria cellularity with basal plasmacytosis and/or presence of basal lymphoid aggregates or a high number of eosinophils─have been associated with a substantial risk of relapse.
14,262-267 The potential value of histopathology to predict relapses and to adequately evaluate the level of inflammation may have implications in therapeutic management. 51, 268 Histological mucosal healing is distinct from endoscopic mucosal healing. Several studies have reported a higher sensitivity for histological diagnosis, with the microscopic analysis yielding more severe diagnoses than those suspected at endoscopy. 266, [269] [270] [271] Histological and endoscopic activity scores closely correlate in severe and inactive disease, but important misclassifications exist for mild disease. 270 The value of histopathology as the [primary or secondary] endpoint to assess disease activity is frequently overlooked in clinical trials. 257, 272, 273 
Microscopic features-upper gastrointestinal tract
Minimal to mild non-specific and focally enhanced gastritis may be present in children and adolescents diagnosed with UC.
255,274-279
Section 5. Extra-intestinal Manifestations
There follows extracts and updates of the ECCO guideline on EIMs 7 and anaemia. 
Anaemia
Anaemia is common in UC, found in 21% of all patients. 
Diagnosis of anaemia
The most common forms of anaemia in UC are iron deficiency anaemia [IDA] , anaemia of chronic disease, and a combination of both.
281,282 Vitamin B 12 or folate deficiency, haemolytic anaemia, and drug-induced anaemia are less prevalent forms, but should also be considered. 283 Anaemia is defined by the World Health Organization as a decline in blood haemoglobin to a concentration of < 12 g/dl [120 g/l] in women and < 13 g/dl [130 g/l] in men. 15, 284 All UC patients should be screened for anaemia, and this screening should include a full blood count, serum ferritin, and CRP levels. Diagnosis of peripheral arthropathy and/or enthesitis associated with ulcerative colitis is based on signs of inflammation and exclusion of other specific forms of arthritis [EL3] 298 Type I peripheral arthropathy is pauci-articular and typically affects less than five large joints in an asymmetrical pattern. This arthritis is acute and self-limiting, and is associated with intestinal disease activity. Type II peripheral arthropathy is a symmetrical and polyarticular arthritis, which typically affects more than five small joints, is independent of UC activity, and can persist for months to years.
Axial arthropathy
Axial arthropathy includes sacroiliitis and spondylitis. 
Treatment of arthropathy related to ulcerative colitis
The target of UC-associated arthritis management is the reduction of inflammation, alleviation of pain, and prevention of disability. So far, no single prospective controlled trial in IBD patients is available. [305] [306] [307] [308] In type I arthritis, successful treatment of the underlying UC flare usually resolves symptoms within weeks. Patients may further benefit from sulphasalazine, rest, and physiotherapy. Patients with type II arthritis usually require NSAIDs or systemic corticosteroids for symptom control. Treatment decisions for axial arthropathy should be shared with a rheumatologist. Sulphasalazine, methotrexate, and azathioprine are considered to be ineffective in AS with axial symptoms. 309 In patients with active AS refractory to or intolerant of NSAIDs, anti-tumour necrosis factor [TNF] agents are recommended. The efficacy and safety of infliximab [IFX] , adalimumab, and golimumab in AS are now well established. 156, 303, [310] [311] [312] [313] [314] [315] [316] [317] [318] The American College of Rheumatology/Spondylitis Association do not recommend any particular NSAID as the preferred choice to decrease the risk of worsening the underlying IBD. They do recommend treatment with anti-TNF monoclonal antibodies, although not etanercept. 
Metabolic bone disease
Diagnosing osteoporosis is based on bone densitometry [T-score < -2.5], which should be assayed in all patients with persistently active UC, especially if repeatedly exposed to corticosteroids or with long disease duration. Calcium 
Cutaneous manifestations
Erythema nodosum
Erythema nodosum usually affects the extensor surfaces of the lower extremities, particularly the anterior tibial areas, and has a symmetrical distribution. 320 It is closely related to disease activity, and its treatment is based on that of the underlying UC. Systemic corticosteroids are usually required. In resistant or recurrent cases, immunomodulation or anti-TNF may be used.
321,322
Pyoderma gangrenosum
Pyoderma gangrenosum lesions are often preceded by trauma, a phenomenon known as pathergy.
323 They most frequently occur on the shins and adjacent to postsurgical stomas. The correlation of pyoderma gangrenosum with disease activity is controversial.
324
Corticosteroids [topical and/or systemic] are considered to be the first line of treatment. IFX has been effective [325] [326] [327] and adalimumab has led to successful outcomes in reported cases, therefore anti-TNF treatment should be considered if a rapid response to corticosteroids is not achieved. Topical or oral calcineurin inhibitors are an alternative, but dermatological advice is recommended prior to its prescription.
328,329
Information on Sweet's syndrome and anti-TNF-induced skin inflammation can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.
7,320,330-341
Ocular manifestations
Episcleritis generally parallels UC activity. It can be self-limiting and usually responds to topical corticosteroids and NSAIDs prescribed alongside treatment of the underlying UC.
342 Simple episcleritis does not require referral to an ophthalmologist and may self-resolve. Uveitis has potentially more severe consequences. When related to UC, uveitis is frequently bilateral, has an insidious onset, and is long lasting. 342 The possibility of progression to loss of vision should prompt urgent referral to an ophthalmologist. Treatment usually consists of topical or systemic corticosteroid or NSAIDs.
342 Immunosuppressive and anti-TNF treatment have each been reported to be of value in resistant cases [see statements 4A & B in Harbord et al. 7 ].
Hepatobiliary disease
PSC constitutes the most important hepatobiliary condition among UC patients. 343 However, peri-cholangitis, steatosis, chronic hepatitis, cirrhosis, and gallstone formation are also over-represented in these patients. Many of the drugs used to treat UC have the potential to cause hepatotoxicity. PSC is a major risk factor for both cholangiocarcinoma and colon cancer.
344 ]. Older age is an independent risk factor for OI and OI-related adverse events in UC. 364, 365 Corticosteroids increase the risk of OI when administered in a dosage greater than 20 mg of prednisolone daily for more than 2 weeks. 366, 367 All IMs used for IBD increase the hazard of OI, and the use of more than one IM at a time may carry an increased risk of more than 14-fold. ]. [375] [376] [377] UC patients should also be tested for HCV-Ab and, if positive, the result should be confirmed by HCV-RNA detection. IMs per se do not worsen HCV infection, unless a concomitant infection associated with HBV or HIV is present, 378 but they can worsen the liver toxicity of medications in HCV-Ab positive subjects.
Information on CMV, HSV, VZV, EBV, HPV, or influenza virus can be found in Supplementary material, available as Supplementary data at ECCO-JCC online. Anti-TNF therapy should be withdrawn during infection, and infectious disease experts should be consulted before reintroducing IM.
Parasites and fungal agents
IMs are independent predictors of severe C. difficile-associated disease. 11, 413, 413 Faecal microbiota transplantation is safe in UC. 414, 415 Fidaxomycin has been shown to be non-inferior in terms of clinical cure to vancomycin and showed a lower recurrence rate of C. difficile. 416 In addition to an increased risk for infection with C. difficile, patients with inflammatory bowel disease are 33% more likely to experience C. difficile recurrence. 
Section 8. Surveillance for Colorectal Cancer in Ulcerative Colitis
Risk of colorectal cancer in ulcerative colitis
Although it is generally accepted that long-standing UC is associated with an increased risk of CRC, the reported risk estimates vary widely between studies. In 2001, Eaden et al. described a meta-analysis including 116 studies 463 and concluded that after 30 years of disease duration the cumulative risk was 18%. Another meta-analysis revealed that the pooled SIR [standardised incidence ratio] of CRC in UC patients was 2.4. 464 However, the risk of CRC may have been declining over time. 465, 466 An Australian study has reported a CRC cumulative incidence of 1% at 10 years, 3% at 20 years, and 7% at 30 years. 467 This may reflect the increased implementation of surveillance strategies, the introduction of drugs that control inflammation more effectively, or the changing approach to maintenance therapy or colectomy. 13 Although it has been stated that CRC is rarely encountered when disease duration falls below 8 years, a significant number of tumours may still develop by this time, 468, 469 especially in patients who are older at colitis onset or in patients with PSC. Patients with extensive colitis carry the highest risk of CRC, whereas left-sided colitis patients present an intermediate risk. CRC risk is not increased in patients with UC limited to the rectum. 463, 470 Of note, histological extent, even without endoscopically visible abnormalities, may be an important determinant for CRC risk.
471,472
The most consistent risk factors reported for CRC are PSC [with an increased absolute risk of up to 31%] 473-477 and histological disease activity. 50, 51 Post-inflammatory polyps may be markers of previous inflammatory severity, and have also been found to be a strong risk factor. 247, 480 Family history of CRC is associated with an increased risk, although the risk varies across studies. 474, 479 Jess et al. Given that an increased risk of CRC is associated with dysplastic change in colonic mucosa, surveillance colonoscopy programmes have been developed in order to reduce CRC-associated morbidity and mortality. These surveillance programmes involve not only a systematic colonoscopic assessment, but also a revision of the patients' symptoms, medications, and laboratory test results, as well as an update of personal and family medical histories. At the onset of these programmes, an initial screening colonoscopy is performed to reassess disease extent and confirm the absence of dysplastic lesions.
Effectiveness
The efficiency of surveillance colonoscopy programmes has yet to be assessed by randomised controlled trials. However, a large number of case series suggest a positive impact. 13, 472, 481 Reduced CRC incidence reported in recent studies may be proof of their efficiency, although other potential factors [including better disease control] may also be relevant.
114 A systematic review was unable to demonstrate a benefit of surveillance programmes in the prevention of CRC-related death in UC when limiting the analysis to studies that included a control group.
114
Two large case series have shown improved survival in surveillance patients due to an early detection of CRC. 466, 482 Three retrospective case control studies have shown a correlation between surveillance colonoscopy and reduced odds ratio of CRC. 478, 483, 484 Unequivocal evidence for the benefit of surveillance colonoscopy is still lacking.
Initial screening colonoscopy and surveillance schedules
ECCO statement 8A
The risk of colorectal cancer in ulcerative colitis is increased compared with the general population. 
]
Screening colonoscopy should be offered over 8 years following the onset of symptoms to all patients to reassess disease extent and exclude dysplasia [EL 5]
ECCO statement 8E
When disease activity is limited to the rectum without evidence of previous or current endoscopic and/or microscopic inflammation proximal to the rectum, inclusion in a regular surveillance colonoscopy programme is not necessary [EL2]
ECCO statement 8F
In patients with concurrent primary sclerosing cholangitis, annual surveillance colonoscopy should be performed following the diagnosis of primary sclerosing cholangitis, irrespective of disease activity, extent, and duration [EL3]
Consensus on Diagnosis and Management of Ulcerative Colitis
Supporting information on risk factors for CRC with and without dysplasia on biopsies can be found in Supplementary materials, available as Supplementary data at ECCO-JCC online. 3, 13, 49, 50, 473, [485] [486] [487] [488] [489] [490] [491] [492] [493] [494] [495] 
Colonoscopy
As happens with screening colonoscopies in the otherwise healthy population, the quality of the preparation in UC patients significantly affects the lesion detection rate. 496 Good bowel preparation is essential for an efficient surveillance colonoscopy. Repetition of the colonoscopy should be considered when excess faecal residue is present.
Endoscopic equipment, patient preparation, and diagnostic techniques have advanced considerably during recent years. High-resolution equipment improves imaging quality, and may therefore improve the dysplasia detection rate. In fact, a recent colitis surveillance study has shown that high-definition colonoscopy improves dysplasia detection in comparison with standard definition. 497 Targeted biopsies have been shown to be non-inferior to random biopsies for neoplasia detection rate per colonoscopy in a randomised controlled trial [RCT] . 498 Dysplasia detection in surveillance colonoscopy can be improved by spraying dyes that highlight subtle changes in the colonic mucosa architecture. 499 Using this technique, random biopsies of apparently normal mucosa are of negligible additional value although they do enable an assessment of microscopic disease extent and activity.
The chromo-endoscopic diagnostic yields are similar using methylene blue or indigo carmine. 503 Another meta-analysis has focused on the diagnostic accuracy of chromo-endoscopy compared with that of histology, and has reported a sensitivity of 83.3% and a specificity of 91.3% for chromo-endoscopy in detection of intraepithelial neoplasia.
504 Superiority of chromoendoscopy compared with white light endoscopy for dysplasia detection has also been shown in real-life studies outside clinical trials. 505 This finding does not vary with operator familiarity or with the availability of high-resolution endoscopy. Currently narrow band imaging as well as endomicroscopy cannot currently be recommended for dysplasia screening in IBD. Additional information can be found in Supplementary materials, available as Supplementary data at ECCO-JCC online. [506] [507] [508] [509] [510] 8.4. Chemoprevention
Mesalamine and colorectal cancer
Additional information can be found in Supplementary material, available as Supplementary data at ECCO-JCC online. 6, 245, 474, 478, 484, 486, [511] [512] [513] [514] [515] [516] [517] [518] [519] [520] [521] 
Patient selection for chemoprevention with 5-ASA
In a nested case-control study of the CESAME cohort, adjusted for the propensity of receiving 5-ASA, a sub-analysis was performed in IBD patients with or without long-standing [> 10 years] and extensive [> 50% of colonic mucosa at any time] colitis.
522
The protective odds ratio was significant for patients with longstanding extensive colitis [OR: 0.5; 95% CI: 0.2-0.9] although it was not in the remaining patients [OR: 0.8; ]. This suggests a chemopreventive effect of 5-ASA in patients with known risk factors for dysplasia or cancer. However, statements on the chemopreventive effect of 5-ASA in UC are not restricted to high-risk individuals, 6, 40, 485 which justifies lifelong chemoprevention from diagnosis in all patients, except for those with isolated proctitis. 6, 40, [49] [50] [51] 245, 471, 472, 485, 512, [523] [524] [525] [526] Additional information can be found in Supplementary material, available as Supplementary data at ECCO-JCC online. 6, 40, [49] [50] [51] 238, 456, 458, 465, 469, 494, [505] [506] [507] 
Immunosuppressants
IMs [e.g. thiopurines and MTX] and biologics [anti-TNF] could theoretically either increase the risk of CRC via immunosuppression, or be chemopreventive via a reduction of chronic mucosal inflammation. There are no data for MTX or anti-TNF, and the data for thiopurines are conflicting. [49] [50] [51] 478, 511, 519, [527] [528] [529] These included the published studies specifically designed to address the chemopreventive effect of thiopurines on the risk of CRC in IBD. 528, 529 Overall, a recent meta-analysis failed to show a significant chemopreventive effect of thiopurines [OR: 0.87 
Microscopic patterns of dysplasia
The current, widely used definition of dysplasia was proposed by Riddell et al. in 1983. 537 Dysplasia was defined as an unequivocal neoplasia of the epithelium confined to the basement membrane, without invasion into the lamina propria. Dysplasia is the best and most reliable marker of an increased risk of malignancy in patients with IBD.
538 Dysplasia [intraepithelial neoplasia] is now generally classified according to the grade of neoplastic change into three morphological categories: 'indefinite', 'low-grade' [LGD], or 'high-grade' [HGD] . 537 However, dysplasia almost certainly evolves along a progressive [continuous] scale rather than in discrete categories. This contributes to the significant degree of variability in interpretation of the grade of dysplasia even among experienced gastrointestinal pathologists.
539,540 Levels of agreement are highest for the category of HGD and for specimens considered negative for dysplasia, and lower for specimens in the indefinite and LGD categories. These limitations in the assessment of dysplasia have led to the recommendation that histological slides should be reviewed by a second expert gastrointestinal pathologist.
Macroscopic patterns of dysplasia
There is inconsistency in the literature about the definitions used to designate the macroscopic characteristics of dysplastic lesions in UC. 493, 536 Terms such as dysplasia-associated lesion or mass [known as 'DALM'], adenoma-like, non-adenoma like, and flat, often cause confusion among endoscopists as they are often used to describe a variety of differently shaped lesions. Thus, in agreement with the SCENIC international consensus, these terms should be abandoned. 541 Dysplasia detected during surveillance procedures should be classified into three categories: polypoid, non-polypoid, and endoscopically invisible. A polypoid lesion refers to pedunculated [Paris type Ip-attached to the mucosa by a stalk] or sessile [Paris type Is-not attached to the mucosa by a stalk and the entire base is contiguous with the mucosa] lesions that protrude from the mucosa into the lumen ≥ 2.5 mm.
541 These lesions are usually endoscopically removable by routine endoscopic methods. 40, 485 'Non-polypoid' lesion refers to Paris type IIa [superficially elevated < 2.5mm], IIb [flat-no protrusion], IIc [depressed], velvety patches, plaques, irregular bumps and nodules, wart-like thickenings, stricturing lesions, and broad-based masses, 493,542-544 and may not be amenable to removal by colonoscopic polypectomy. Polypoid and non-polypoid dysplasia are differentiated on the basis of their gross [endoscopic] appearance. Histological features may be helpful, 545 although both types of lesions may appear identical. 546, 547 Endoscopically invisible dysplasia refers to dysplasia found during histological examination in the absence of a visible lesion at colonoscopy.
Management of endoscopically visible dysplasia
Polypoid dysplasia arising in a colonic segment currently, or previously, affected by colitis can be adequately treated with polypectomy and continued surveillance. Four studies have shown no significant difference in the incidence of polyp detection on followup between patients with UC and polypoid dysplasia, and patients with UC and a sporadic adenoma, or between either of these two groups of UC patients and a non-UC sporadic adenoma control group. 3, 245, 545, 548, 549 Recent literature continues to support this strategy. Data from a St Mark's Hospital, UK, cohort of 172 patients with LGD showed that the cumulative incidence of developing HGD or CRC at 5 years after the initial detection of polypoid dysplasia was 6%.
472 A meta-analysis of 10 studies comprising 376 patients demonstrated that the pooled incidence of CRC after endoscopic resection of polypoid dysplasia was 5.3 cases per 1000 patient-years of follow-up [95% CI: 2.6-10.1 cases]. 550 Thus, provided that the polypoid lesion can be completely excised, shows absence of dysplasia at the margins of the specimen, and there is no evidence of
ECCO statement 8K
Presence of low-grade or high-grade dysplasia should be confirmed by an independent gastrointestinal specialist pathologist [EL 5]
ECCO statement 8L
Polypoid dysplasia can be adequately treated by polypectomy provided the lesion can be completely excised, and there is no evidence of non-polypoid or invisible dysplasia elsewhere in the colon [EL 2]
ECCO statement 8M
Non-polypoid dysplastic lesions can be treated endoscopically in selected cases. If complete resection can be achieved, with no evidence of non-polypoid or invisible dysplasia elsewhere in the colon, continued surveillance colonoscopy is reasonable [EL 5] . Every other patient with non-polypoid dysplasia should undergo colectomy, regardless of the grade of dysplasia detected on biopsy analysis [EL 2]
ECCO statement 8N
Polyps with dysplasia that arise proximal to segments with macroscopic or histological involvement are considered as sporadic adenomas and should be treated accordingly [EL 2] non-polypoid or invisible dysplasia elsewhere in the colon, colectomy is not necessary. It is important to obtain biopsies from the immediate surrounding flat mucosa to ensure that there is no adjacent dysplasia. Patients undergoing endoscopic resection for polypoid lesions have an approximately 10-fold risk of developing further dysplasia. 550 Therefore, close monitoring preferably with chromo-endoscopy is recommended at 3-6 months before reverting to annual surveillance. Partial colonic resection, if dysplasia is visible and not endoscopically resectable, or future surveillance in the context of LGD might also be a potential option.
Non-polypoid dysplasia is a more ominous finding. The natural history of these lesions was recently studied in depth, where authors investigated 172 UC patients diagnosed with LGD in the St Mark's Hospital surveillance cohort. 472 The cumulative incidence of HGD or CRC development after 5 years was 6.0% for polypoid dysplasia and 65.2% for non-polypoid dysplasia. Furthermore, nonpolypoid dysplasia was more likely to be multifocal compared with polypoid lesions and often progressed to synchronous CRC. These data support findings from earlier studies, where there was a strong association of metachronous or synchronous carcinoma with nonpolypoid dysplasia, ranging from 38% to 83%. 536 For this reason, it is generally recommended that patients with UC and endoscopically unresectable non-polypoid dysplasia should undergo immediate colectomy, regardless of the grade of dysplasia detected by biopsy analysis. Currently, there are no dedicated studies investigating longterm outcome of patients who undergo endoscopic resection for non-polypoid dysplasia. A subgroup analysis of the aforementioned St Mark's study revealed that one of eight patients [12.5%] who underwent endoscopic resection for small non-polypoid LGD [all < 1 cm] developed Dukes' A CRC with a median follow-up time of 44 months. 472 Although this should be interpreted with caution given the small number of cases, it implies that colectomy may not always be necessary for a subgroup of patients diagnosed with nonpolypoid dysplasia. Furthermore, one study showed that patients are likely to refuse colectomy if they were told that they have dysplasia and have 20% chance of having CRC 'right now'.
551 Based on this, despite the lack of evidence, continued surveillance can be considered reasonable if the non-polypoid lesion can be resected in full and if there is no evidence of invisible or non-polypoid dysplasia elsewhere in the colon. In all cases, a full discussion should occur with the patient so that they are made aware of the potential risk and benefits of taking either approach [i.e. endoscopic resection versus colectomy]. Again, close monitoring, preferably with chromoendoscopy, is recommended at 3 to 6 months before reverting to annual surveillance. Finally, if a dysplastic polyp occurs in an area proximal to the microscopic level of inflammation, with no dysplasia in flat mucosa, it can be regarded as a sporadic adenoma and treated accordingly.
549,552
Management of endoscopically invisible dysplasia
Macroscopically invisible dysplasia describes dysplasia within random biopsies in the absence of visible lesions during colonoscopy. It is difficult to estimate its true risk as many 'invisible' dysplastic lesions reported in previous studies were recorded in the pre-video endoscopic era. This makes it difficult to know whether these represent truly invisible dysplasia or merely subtle non-polypoid lesions that were previously undetected, but that could now be visualised with newer techniques. However, there is indirect evidence suggesting that invisible dysplasia is becoming rare. In the Bernstein et al. review of 10 prospective studies performed in the pre-video endoscopic era [published in 1994] , the majority of dysplasia was invisible [272/312 = 87%] .
515 This is in contrast with the recent data from the St Mark's cohort study of UC patients diagnosed with LGD, where only 16 out of 172 [9%] had invisible dysplasia.
These observations indicate that the majority of invisible dysplasia reported in older studies may have been subtle lesions undetected by older endoscopes. Based on this observation, when dysplasia is identified from random biopsies, the patient should be referred to an endoscopist with expertise in IBD surveillance to have a repeat examination preferably with chromo-endoscopy using a high-definition endoscope, to determine whether a well-circumscribed lesion exists and can be resected and to assess for synchronous dysplasia. Of note, the recent study from St Mark's reported that the detection rate for non-polypoid lesions was significantly higher with chromo-endoscopy compared with standard white-light colonoscopy. Although this should be interpreted with caution given that this was not a dedicated study, it nevertheless supports reassessing these patients with the more advanced techniques.
If a visible lesion is found in the same region of the colon as the invisible dysplasia, patients should be managed appropriately as described in section 8.5.3. If no visible lesion is identified, its management depends on the grade of initial dysplasia. It is generally accepted that the immediate and subsequent risk of CRC in patients with invisible HDG is high enough to warrant recommendation for colectomy [reviewed in 2012 ECCO guidelines 3 ]. Recommendations on the optimal management of UC patients with endoscopically invisible LGD are more controversial, as the risk of progression to more advanced neoplasia varies greatly in the literature [reviewed in 2012 ECCO guidelines 3 ]. This can be as low as 3% after 10 years 489 to as high as 53% at 5 years 553 since the date of initial detection. In the recent St Mark's series, the 5-year progression rate was 21.9%, which was higher than that of polypoid lesions [6.0%] but lower than that of non-polypoid lesions [65.2%] . 472 Thus, given that the relevance of the existing evidence is questionable and that reports are contradictory, the current evidence is insufficient to assess the balance of risk and benefit of colectomy for endoscopically invisible LGD. The decision to undergo colectomy versus continued surveillance in patients with flat LGD should be individualised and discussed at length between the patient, the gastroenterologist, and the colorectal surgeon. Colectomy will eradicate the risk of CRC, but if a patient is unwilling to undergo colectomy, annual surveillance is recommended. 485 The 2013 ECCO endoscopy guideline recommended that a patient with confirmed LGD detected in mucosa without an associated endoscopically visible lesion should undergo repeat chromo-endoscopic colonoscopy with additional random biopsies within 3 months.
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Section 9. Surgery
General
This section summarises the ECCO consensus guidelines on surgery in UC patients.
12 It should be noticed that the level of evidence of these surgical guidelines is rather modest because robust evidence stemming from randomised studies is still lacking in the literature.
Surgery for UC has been refined to offer a better quality of life to patients who need to undergo a colectomy. Until the early 1980s, and apart from the sporadic use of ileo-rectal anastomosis, the gold standard for surgery was a procto-colectomy with an ileostomy. The Kock continent ileostomy was introduced in the late 1960s but has never achieved universal acceptance, in spite of the fact that the quality of life when compared with procto-colectomy with a conventional stoma seemed to be clearly higher. 554 In the past 20 years, the new gold standard is the restorative procto-colectomy with an ileal pouch-anal anastomosis [IPAA] , offering patients an unchanged body image with no stoma and a preserved anal route of defaecation.
555
.Nevertheless, bowel function is not restored, and therefore both functional outcomes and quality of life after an IPAA should be compared with those after an ileostomy. Joint care including senior surgeons and senior gastroenterologists remains essential for the safe management of acute severe colitis. Whereas medical therapy is effective in many cases, there is clear evidence that a delay in appropriate surgery is detrimental to patient outcomes. 557 A staged procto-colectomy [with subtotal colectomy first] is considered to be a wise first step in the surgical treatment of acute severe colitis or if patients have received prolonged steroid therapy [over 20 mg of prednisolone/day for more than 6 weeks]. A subtotal colectomy with an ileostomy will spare patients from the burden of colitis. As a consequence, they will regain general health, normalise nutrition, and have the time to consider carefully the options of an IPAA or of a permanent ileostomy. A preliminary subtotal colectomy also allows the clarification of the pathology, definitively excluding Crohn's. Subtotal colectomy is a relatively safe procedure even in critically ill patients. [558] [559] [560] In a recent systematic review of laparoscopic versus open colectomy for non-toxic colitis, laparoscopic surgery resulted in less wound infections and intra-abdominal abscesses and a shorter hospital stay. 561 Emerging evidence supports that the same holds true for emergency colectomy.
562,563
Managing the rectal remnant
Critical aspects need to be considered when performing a subtotal colectomy leaving a rectal remnant. Leaving as little rectum as possible [i.e. dividing the middle rectum within the pelvis] is not recommended, because such an approach will impose difficulties at subsequent proctectomy, with a probable increase in the risk of pelvic nerve injury. The alternatives are to divide the rectum at the level of the promontory [i.e. at the recto-sigmoid junction], or to leave the distal part of the sigmoid colon in situ. This allows the bowel to be anchored to the anterior abdominal wall, which facilitates its subsequent identification and dissection or its relocation through the abdominal fascia, either closed in the subcutaneous fat or brought forward as a mucous fistula. The latter option is considered to be safe, as no closed bowel is left within the abdomen. However, a mucous fistula results in an extra stoma for the patient, which may not be easily managed. 564 Closing the stump and leaving it within the subcutaneous fat is also a safe approach, although the skin should be allowed to heal through secondary intention in order to avoid wound infection. 565 There are no studies yet on the risk of subsequent inflammation or bleeding after leaving different lengths of rectum or recto-sigmoid colon in situ. When the rectum is transected within the abdominal cavity at the promontory level, it is advisable to perform transanal rectal drainage for a few days to prevent a 'blowout' of the rectal stump following mucous retention.
Site of anastomosis for restorative procto-colectomy
A common complication when using a stapling technique to perform an ileo-anal anastomosis is leaving a remnant of anorectal mucosa above the dentate line. This can be a cause of persistent inflammation ['cuffitis'] , with pouch dysfunction and a risk of dysplasia or, very rarely, cancer. 393, 566 When well performed, the low-stapled anastomosis seems to have better outcomes, particularly with regard to soiling, faecal leakage, and social restriction. 567, 568 Further information on anastomotic technique and site in case of neoplasia complicating colitis can be found in Supplemental material, available as Supplementary data at ECCO-JCC online.
569-572
Role of covering ileostomy for restorative procto-colectomy
One of the main complications of IPAA surgery is the occurrence of a leak at the suture line of the anastomosis or pouch. This is also a complication that is most likely to compromise the clinical and functional outcomes of the operation. Whether the consequences of a leak can be ameliorated by a covering ileostomy or not is still under debate. 573, 574 However, there is evidence that defunctioning the distal anastomosis may reduce the incidence of a leak. 575 Nevertheless, it might be clear during pouch surgery that the morbidity associated with a stoma does not justify its use [e.g. when there is a thick abdominal wall and a short small bowel mesentery], as long as no problems have occurred when constructing the anastomosis.
576-579
Number of procedures to maintain competency
It has been shown that institutions where a larger number of complex surgical procedures that demand sophisticated perioperative care are performed, have better outcomes, 580 which is also true for pouch surgery.
581
Moreover, it is clear that high-volume institutions manage adverse events better, which leads to better pouch salvage in the face of complications. 
587-589
Timing of clinical follow-up is adjusted to the development of these conditions, and no standardised schedule is currently available. In patients with signs and symptoms compatible with pouchitis [liquid stools, urgency, tenesmus, pelvic discomfort, or electrolyte imbalance], pouchoscopy should be performed in order to discriminate between pouchitis and the other conditions listed above. 590 The timing of the endoscopic follow-up should be adjusted to each patient's specific condition. 588,592 Dysplasia was equally frequent in the pouch and rectal cuff or anal transitional zone. Dysplasia and cancer identified before or at operation seemed to be significant predictors for the development of pouch dysplasia. Data from this systematic review have been confirmed by others, indicating that even if the indication for colectomy was dysplasia or cancer, the risk of having dysplasia in the rectal cuff or pouch remains very low. 593, 594 No specific follow-up is therefore recommended after restorative procto-colectomy in the absence of risk factors.
9.4. Fertility and delivery in patients with a restorative procto-colectomy 9.4.1. Impact of pelvic surgery on fecundity Active UC is associated with poor sexual function. Two prospective studies demonstrated an improvement in sexual function in both genders 12 months after IPAA when compared with preoperative levels. 429, 595 On the other hand, it has been convincingly demonstrated in three cohort studies that female fecundity is reduced after an IPAA. [596] [597] [598] [599] This reduction is most likely associated with adhesions affecting the fallopian tubes. 600 The magnitude of this problem is under debate, with one study showing more than 70% of fecundity reduction, whereas others point towards approximately 30%. Growing evidence suggests that laparoscopic IPAA is technically feasible and may limit the negative consequences as to female fecundity. [601] [602] [603] [604] Interestingly, data from a study on patients with familial adenomatous polyposis have compared the fecundity reduction in women after an ileo-rectal anastomosis [IRA] or after an IPAA, and have shown that IRA carries no associated reduction in fecundity. 605, 606 Again, this appears to be because an IRA does not induce pelvic adhesions to the same extent as an IPAA. Furthermore, there is evidence that IRA provides a safe and functionally acceptable outcome. 607, 608 In male patients, retrograde ejaculation and erectile dysfunction are the main, but still rare, sexuality-and fertility-related complications that may occur after an IPAA. Both complications are avoided when an IRA is chosen. 609 When making the decision on the type of surgical approach, concern about IRA should be considered [see section 9.5.3].
Information on mode of delivery for patients with restorative procto-colectomy can be found in Supplementary materials, available as Supplementary data at ECCO-JCC online. 16, [610] [611] [612] [613] [614] [615] [616] [617] 9.5. Surgical choices in addition to restorative procto-colectomy 9.5.1. Age IPAA may carry a higher risk for comorbidity in patients aged > 65 years. Still, the procedure is apparently safe and effective in this age group, and remains the surgical technique of choice. 618 However, an increased frequency of long-term complications [e.g. pouchitis, anastomotic stricture] has been reported to occur in elderly patients who undergo IPAA.
619 Deterioration in pouch function with faecal incontinence occurs with advancing age, and this may be more
ECCO statement 9F
Annual pouchoscopy is recommended in patients with risk factors such as neoplasia and primary sclerosing cholangitis. No specific pouch follow-up protocol is required in asymptomatic patients [EL 3]
ECCO statement 9G
In a fertile female patient, alternative surgical options such as subtotal colectomy and end ileostomy or ileorectal anastomosis should be discussed with the patient, because fecundity is at risk after ileal-pouch anal anastomosis [EL3] . A laparoscopic approach is associated with better preservation of female fertility and is preferred [EL3]
ECCO statement 9H
There is no age limit for performing an ileal-pouch anal anastomosis as long the patient retains good anal sphincter function [EL 5]
ECCO statement 9E
Early pouchoscopy is recommended in symptomatic patients with pouch dysfunction, in order to distinguish between pouchitis and other conditions [EL 4] pronounced in the elderly. Many surgeons have discredited the Kock's pouch procedure given its elevated rate of reoperation, as approximately half of the patients will need reoperation, with nipple valve sliding being the most common indication. Currently however, most series present a 10-year continent pouch survival of around 90%. 624, 625 Quality of life with a Kock's pouch seems superior to that following an end-ileostomy. According to a study from the Cleveland Clinic, patients with an end-ileostomy were more than twice as likely to report social, work, and sexual restrictions as those who underwent a Kock's continent ileostomy. 
Ileo-rectal anastomosis
The reluctance of many surgeons to perform an IRA in UC patients 626 is justified by the good long-term functional outcome that follows an IPAA compared with the unpredictable functional outcome after an IRA in a noncompliant and inflamed rectum, as well as by the fear of a subsequent rectal cancer. IRA is a less complex procedure with lower morbidity rates and with reasonable clinical results in highly selected patients. Patients considered for IRA are those that present a relatively spared rectum [or a healed rectum under medical therapy], good rectal compliance, and normal sphincter tone. In these patients, defaecation habits are almost the same as after an IPAA procedure, although urgency seems to be more common in the IRA published series [22-33%] . 607 Urgency is the most common cause of IRA failure. The reported probability of having a functioning IRA ranges from 74% to 84% at 10 years and from 46% to 69% at 20 years. 626, 627 Surveillance of the retained rectum is necessary. 
Non-inflammatory pouch dysfunction and pouch failure
Detailed information on non-inflammatory pouch dysfunction can be found in Supplementary material, available as Supplementary data at ECCO-JCC online. 583, 586, 588, [628] [629] [630] [631] [632] [633] [634] [635] [636] [637] 9.6. Surgery and medication 9.6.1. Perioperative prednisolone Uncontrolled and retrospective studies indicate that patients taking more than 20 mg of prednisolone for > 6 weeks have an increased risk of short-term surgical complications. [638] [639] [640] [641] [642] These studies have shown a five-fold risk of infectious complications and an increased risk of short-term postoperative, pouch-specific complications. Therefore, steroids should be weaned before surgery. If weaning is not possible, then pouch construction should be postponed. All recommendations regarding the rate of steroid reduction after colectomy for acute severe colitis are arbitrary but should avoid acute steroid withdrawal [Addisonian crisis], which in its most severe form is characterised by hypotension, hyponatraemia, and hypoglycaemia. Milder symptoms may be interpreted as a slower than normal recovery from surgery. The rate of tapering depends on the dose and duration of steroids preceding to surgery. For patients who have been taking steroids > 6 months, a dose reduction of 1 mg/week over a period of several months might be necessary. [653] [654] [655] As nearly all data on this subject come from observational studies rather than from randomised controlled trials, there might be significant bias influencing the results. A study from the Mayo Clinic has shown that postoperative anastomotic leaks and pouch-specific and infectious complications were more common in IFX-treated patients then among those who were not prescribed IFX. 649, 650 After adjustment for concomitant therapy and severity of colitis, IFX was the only factor independently associated with infectious complications. Likewise, a more recently published study suggested that patients with previous anti-TNF use had a higher rate of pelvic sepsis after one-stage IPAA. 656 Conversely, a large Danish registry including more than 1200 UC patients who underwent a procto-colectomy did not report a significant increase in complications after surgery for previously IFX-exposed patients.
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ECCO statement 9I
Under optimal circumstances, ileo-rectal anastomosis is a reasonable alternative to ileal-pouch anal anastomosis [EL5] . Advantages such as lower morbidity and preserved female fecundity need to be weighed against the need for rectal surveillance and subsequent protectomy in 50% of cases [EL3]
ECCO statement 9J
Non-inflammatory causes of pouch dysfunction include pouch-anal stricture, pouch fistula, problems with pouch capacity, efferent limb dysfunction [S-pouch] , retained rectal stump, and chronic pre-sacral sepsis. Deciding on appropriate management requires discussion in a multidisciplinary team setting [EL5]
ECCO statement 9K
Preoperative thiopurines or ciclosporine do not increase the risk of postoperative complications [EL3]
The severity of disease and the sequential use of ciclosporine may also influence the postoperative IFX-associated risk. Patients with less severe forms of the disease and low CRP levels seem to benefit most from IFX therapy, 649, [658] [659] [660] and there is particular concern that emergency colectomy within a few weeks of IFX may be associated with more septic complications.
Several studies report the efficacy and safety of ciclosporine and IFX as sequential rescue therapy in patients with steroid-refractory UC. 651, [661] [662] [663] Overall, up to one-third of patients achieve short-term remission, and up to two-thirds avoid short-term colectomy. 662, 663 These rates appear to be similar between patients receiving IFX after ciclosporine failure, and patients receiving ciclosporine after IFX failure. However, 16% of all patients experienced serious adverse events including sepsis, with fatal outcomes and herpetic oesophagitis. 661, 662 There is no clear evidence on whether the risk of infectious complications is dependent on the drug sequence although theoretically IFX after ciclosporine should be safer, as ciclosporine has a much shorter half-life. Although some studies suggest a similar complication rate to that reported with IFX or ciclosporine alone, 662, 663 the risk/benefit ratio of sequential rescue therapy has to be considered carefully in selected patients only, and cannot be recommended routinely. This seems to be especially true if ciclosporine is given as the second rescue therapy after IFX failure. As long as the data on perioperative use of anti-TNF agents remain conflicting, the standing recommendation is to not perform a single stage procto-colectomy with ileo-anal pouch construction in anti-TNF treated patients.
Section 10. Pouchitis
General
Procto-colectomy with an IPAA is the procedure of choice for most UC patients who require colectomy. 587 Pouchitis is a non-specific inflammation of the ileal reservoir and is the most common complication after an IPAA for UC. [588] [589] [590] [591] [592] [593] [594] Its frequency is related to the follow-up duration, occurring in up to 50% of patients 10 years after IPAA. 587, 588, [590] [591] [592] [593] [594] 664, 665 The cumulative incidence of pouchitis in patients with an IPAA following familial adenomatous polyposis is much lower, ranging from 0% to 10%, 666-668 but reasons for the higher frequency of pouchitis in UC patients remain unknown. Moreover, whether pouchitis develops more commonly within the initial years after IPAA or whether the risk increases continuously with follow-up remains undefined.
Symptoms
After procto-colectomy with IPAA, daily median stool frequency is four to eight bowel movements, 587, 588, 590, 591, 623, 669 with about 700 ml of semi-formed/liquid stool passed per day, 588, 623, 669 compared with a volume of 200 ml/day in healthy subjects. Symptoms related to pouchitis include increased stool frequency and liquidity, abdominal cramping, urgency, tenesmus, and pelvic discomfort. 588, 624 Rectal bleeding, fever, and EIM may also occur. Rectal bleeding, however, is more often related to inflammation of the rectal cuff [see section 10.4] 625 than to pouchitis. Faecal incontinence may occur in the absence of pouchitis after IPAA, but is more common in patients with pouchitis. Symptoms of pouch dysfunction in patients with IPAA may be caused by conditions other than pouchitis, including Crohn's disease of the pouch, 670-672 cuffitis, 625 and an irritable pouch, 673 among other conditions. This is why the diagnosis depends on endoscopic and histological findings in conjunction with symptoms.
Endoscopy ['pouchoscopy']
Pouchoscopy and pouch mucosal biopsy should be performed in patients with symptoms compatible with pouchitis, in order to confirm the diagnosis. 624, 674 Patients with an ileo-anal pouch occasionally have a stricture at the pouch-anal anastomosis, so a gastroscope rather than a colonoscope is preferred. Progression into the afferent ileal limb should always be attempted. Endoscopic findings compatible with pouchitis include diffuse erythema, which may be patchy, unlike that observed in UC. Characteristic endoscopic findings also include oedema, granularity, friability, spontaneous or contact bleeding, loss of vascular pattern, mucous exudates, haemorrhage, erosions, and ulceration. 670 Erosions and/or ulcers along the staple line do not necessarily indicate pouchitis. 671, 675, 676 Biopsies should be taken from the pouch mucosa and from the afferent limb above the pouch, but not along the staple line.
Histopathology of pouchitis
Additional information on the histopathology of pouchitis can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.
675-680
Differential diagnosis
The clinical history and biopsies help discriminate between pouchitis, ischaemia, Crohn's disease, and other rare forms of pouch dysfunction such as collagenous pouchitis and C. difficile or CMV pouchitis.
683-685 Secondary pouchitis, caused by pelvic sepsis, usually causes focal inflammation and should be considered. Biopsies taken from the ileum above the pouch may reveal pre-pouch ileitis as a cause of pouch dysfunction, although this usually causes visible ulceration that may be confused with Crohn's disease. 684 The possibility of nonspecific ileitis caused by NSAIDs should also be considered. 
Risk factors for pouchitis and pouch dysfunction
The aetiology of pouchitis remains unclear. Risk factors, genetic associations, and serological markers of pouchitis suggest that a close interaction between the host immune response and the pouch microbiota plays a relevant role in the aetiology of this idiopathic inflammatory condition. 686 [n = 50] . The risk of developing pouchitis was increased when the indication for IPAA was dysplasia, when the patient had never smoked, used NSAIDs, or [perhaps surprisingly] had never used anxiolytics. 682 The risk of a diagnosis of Crohn's disease in the pouch was greatly increased by being a current smoker, and modestly increased with having a pouch of long duration. Cuffitis was associated with symptoms of arthralgia and a younger age. Irritable pouch syndrome is probably under-recognised, although it is a common cause of pouch dysfunction when other causes [including a small volume pouch, incomplete evacuation, and pouch volvulus] have been excluded and investigations are normal. The principal risk factor is the use of antidepressants or anxiolytics, which suggests that
ECCO statement 10A
The diagnosis of pouchitis requires the presence of symptoms, together with characteristic endoscopic and histological abnormalities [EL3] . Extensive ulcerative colitis, primary sclerosing cholangitis, being a non-smoker, pANCA-positive serology, and non-steroidal anti-inflammatory drug use are possible risk factors for pouchitis [EL3] 
